Phase 2 Epilepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have read and understood what the study involves, including its risks, and have agreed to take part by signing a consent form before the study begins.
- People who completed the full earlier study (CB03-154-EP201) without leaving early, met all the rules of that study, had no major protocol issues or side effects that would prevent them from continuing, and whose treatment appeared to be working based on a review of the study data.
- People who, in the opinion of the study doctor, are able to understand spoken and written instructions and are willing and able to follow all study schedules and requirements.
- People who are able to keep accurate daily records (diaries) of their seizures.
Who may not be able to join:
- People who were withdrawn from the earlier study (CB03-154-EP201) for meeting any of its withdrawal rules.
- People who have a medical condition, personal situation, or ongoing side effect from the earlier study that the study doctor believes would put them at unacceptable risk by taking part, or that would prevent them from following the study requirements.
- People who are planning to join another clinical trial involving a different experimental drug, or who plan to use any experimental device for epilepsy treatment, during this study or within 28 days after finishing it.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0390762029
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
To assess the long-term tolerability and safety of CB03-154 in patients diagnosed with epilepsy.; To assess the long-term efficacy of CB03-154 in patients diagnosed with epilepsy.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.